Furthermore, the low level of true disease-specific changes simplifies identification of functionally relevant methylation changes, illustrated here by identification and functional confirmation of SLC22A15 as a tumour suppressor in acute lymphoblastic leukaemia. This evidence concerns the gene SLC22A15 and acute lymphoblastic leukemia.